Morgan Stanley
PHAS

Morgan Stanley’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Morgan Stanley’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-95,763
Closed -$17K – 8129
2022
Q3 		$17K Sell
95,763
-11,003
-10% -$11.2K ﹤0.01% 6878
2022
Q2 		$64K Sell
106,766
-34,102
-24% -$32.6K ﹤0.01% 6504
2022
Q1 		$186K Sell
140,868
-130,409
-48% -$211K ﹤0.01% 5966
2021
Q4 		$708K Buy
271,277
+122,115
+82% +$369K ﹤0.01% 5328
2021
Q3 		$464K Buy
149,162
+20,081
+16% +$67K ﹤0.01% 5547
2021
Q2 		$480K Buy
129,081
+30,620
+31% +$102K ﹤0.01% 5545
2021
Q1 		$340K Sell
98,461
-9,988
-9% -$40.5K ﹤0.01% 5365
2020
Q4 		$365K Buy
108,449
+6,799
+7% +$24.3K ﹤0.01% 5259
2020
Q3 		$356K Sell
101,650
-60,026
-37% -$242K ﹤0.01% 4808
2020
Q2 		$743K Buy
161,676
+76,053
+89% +$337K ﹤0.01% 4380
2020
Q1 		$284K Sell
85,623
-16,961
-17% -$77.6K ﹤0.01% 4709
2019
Q4 		$627K Sell
102,584
-48,870
-32% -$201K ﹤0.01% 4800
2019
Q3 		$631K Buy
151,454
+67,260
+80% +$536K ﹤0.01% 4574
2019
Q2 		$1.1M Buy
84,194
+81,963
+3,674% +$1M ﹤0.01% 4165
2019
Q1 		$21K Buy
+2,231
New +$8.83K ﹤0.01% 6000

Other funds holding PHAS

DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HLA
Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return
IIA
IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Morgan Stanley's PHAS Position: Q4 2022 in Review

Morgan Stanley sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 95,763 shares — an estimated $17K sold.

Morgan Stanley first reported a position in PHAS in Q1 2019 and held it in 15 quarters. The position peaked at $1.1M in Q2 2019. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

  • Morgan Stanley reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Morgan Stanley sold 95,763 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $17K.
  • Morgan Stanley first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q1 2019 and held it in 15 quarters.
  • Morgan Stanley's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $1.1M in Q2 2019.
  • 5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Morgan Stanley's 13F filing for Q4 2022, filed 14 Feb 2023.